Literature DB >> 21549414

Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.

Zhenjie Yin1, Yan Zhang, Yu Li, Tingting Lv, Jie Liu, Xinbo Wang.   

Abstract

Activation of signal transducer and activator of transcription 3 (STAT3) plays important roles in tumorigenesis and tumor development. Previously, we have reported that overexpression of STAT3 potentiates growth, survival and radioresistance of non-small cell lung cancer (NSCLC) cells. The aim of this study was to investigate the prognostic significance of STAT3 expression and its correlation with chemoresistance of NSCLC cells. Semi-quantitative RT-PCR was performed to detect the expression of STAT3 mRNA in 12 NSCLC and corresponding adjacent lung tissues. Immunohistochemistry was performed to detect the expression of STAT3 protein in 76 NSCLC tissue samples. Additionally, the correlation between STAT3 expression and prognosis of NSCLC patients was statistically analyzed. The role of STAT3 in chemoresistance of NSCLC cells was also assessed by the vector-based small interfering RNA. The expression level of STAT3 mRNA in NSCLC tissues was significantly higher than that in corresponding adjacent lung tissues (P<0.05). Positive immunostaining of STAT3 protein was mainly located in the cytoplasm of tumor cells. The expression of STAT3 protein was significantly correlated with tumor differentiation, clinical stage and lymph node metastasis of NSCLC patients. Moreover, the 5-year overall survival rate of patients with high STAT3 expression (42.3%) was significantly lower than that of patients with low STAT3 expression (58.8%; P<0.001). Multivariate analysis using the Cox proportional hazard model showed that high STAT3 protein expression was an independent prognostic factor for NSCLC patients (P=0.021). Furthermore, two stably transfected cell lines (A549/shSTAT3 and SPC-A1/shSTAT3) were successfully established, and RNAi-mediated STAT3 inhibition could significantly increase the sensitivity of NSCLC cells to cisplatin by enhancing caspase-3-dependent apoptosis. Together, the expression of STAT3 might be an independent prognostic marker for NSCLC patients and RNAi-mediated STAT3 inhibition would be a potential strategy for chemosensitization of NSCLC cells.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21549414     DOI: 10.1016/j.acthis.2011.04.002

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  19 in total

Review 1.  HIF-1 at the crossroads of hypoxia, inflammation, and cancer.

Authors:  Kuppusamy Balamurugan
Journal:  Int J Cancer       Date:  2015-04-07       Impact factor: 7.396

2.  STAT3 is associated with lymph node metastasis in gastric cancer.

Authors:  Jingyu Deng; Han Liang; Rupeng Zhang; Dan Sun; Yi Pan; Yong Liu; Li Zhang; Xishan Hao
Journal:  Tumour Biol       Date:  2013-07-04

3.  Disruption of STAT3 by niclosamide reverses radioresistance of human lung cancer.

Authors:  Shuo You; Rui Li; Dongkyoo Park; Maohua Xie; Gabriel L Sica; Ya Cao; Zhi-Qiang Xiao; Xingming Deng
Journal:  Mol Cancer Ther       Date:  2013-12-20       Impact factor: 6.261

Review 4.  Role of STAT3 in lung cancer.

Authors:  Pranabananda Dutta; Nafiseh Sabri; Jinghong Li; Willis X Li
Journal:  JAKSTAT       Date:  2015-01-20

5.  A STAT3-NFkB/DDIT3/CEBPβ axis modulates ALDH1A3 expression in chemoresistant cell subpopulations.

Authors:  Claudia Canino; YuYing Luo; Paola Marcato; Giovanni Blandino; Harvey I Pass; Mario Cioce
Journal:  Oncotarget       Date:  2015-05-20

6.  STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation.

Authors:  Mohini Singh; Neha Garg; Chitra Venugopal; Robin Hallett; Tomas Tokar; Nicole McFarlane; Sujeivan Mahendram; David Bakhshinyan; Branavan Manoranjan; Parvez Vora; Maleeha Qazi; Carolynn C Arpin; Brent Page; Sina Haftchenary; David A Rosa; Ping-Shan Lai; Rodolfo F Gómez-Biagi; Ahmed M Ali; Andrew Lewis; Mulu Geletu; Naresh K Murty; John A Hassell; Igor Jurisica; Patrick T Gunning; Sheila K Singh
Journal:  Oncotarget       Date:  2015-09-29

7.  Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin.

Authors:  Gerhard Hamilton
Journal:  Cancers (Basel)       Date:  2014-07-08       Impact factor: 6.639

Review 8.  Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis.

Authors:  Pin Wu; Dang Wu; Lufeng Zhao; Lijian Huang; Gang Shen; Jian Huang; Ying Chai
Journal:  Oncotarget       Date:  2016-04-12

9.  Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.

Authors:  A-C Tsai; C-Y Wang; J-P Liou; H-C Pai; C-J Hsiao; J-Y Chang; J-C Wang; C-M Teng; S-L Pan
Journal:  Cell Death Dis       Date:  2014-04-10       Impact factor: 8.469

10.  Clinical and prognostic significance of signal transducer and activator of transcription 3 and mucin 1 in patients with non-small cell lung cancer following surgery.

Authors:  Zhi-Gang Sun; Min Zhang; Fei Yang; Wei Gao; Zhou Wang; Liang-Ming Zhu
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.